Diagonal Therapeutics raises $128M in Series A financing led by BVF Partners and Atlas Venture to develop agonist antibodies for hereditary hemorrhagic telangiectasia (HHT) and other severely debilitating diseases.

Apr 03, 2024•over 1 year ago

Amount Raised

$128 Million

Round Type

series a

CambridgeTherapeuticsBiotechnologyHealth Care

Investors

Checkpoint CapitalVelosity CapitalViking Global InvestorsFrazier Life SciencesRa Capital ManagementLightspeed Venture PartnersAtlas VentureBvf Partners

Description

Diagonal Therapeutics, a biotechnology company, has launched with $128 million in Series A financing. The funding will support further advancement of the company’s proprietary DIAGONAL platform and pipeline of novel therapeutics to value-creating milestones.

Company Information

Company

Diagonal Therapeutics

Location

Cambridge, Massachusetts, United States

About

Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. For more information, please visit www.diagonaltx.com.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends